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Introduction
The process of apoptosis is critical to the development and homeostasis of multicellular organisms.
It provides a mechanism for loss of cells during organogenesis and provides a pathway for removal of cells that are undergoing inappropriate proliferative events or have received unrepairable DNA damage. A theme in cancer biology is that cellular transformation requires the establishment of survival pathways that limit the process of apoptosis. Recent studies have revealed that one such survival pathway is established through the action of the transcription factor NFkB. NFkB plays important roles in activation of genes in response to cytokines and other stimuli, and has been well characterized with respect to its role in inflammatory diseases. Cytokines such as TNF-a activate two pathways, one that activates a cell death response, and one that activates a survival response that is dependent upon NFkB. This finding has renewed interest in the development of inhibitors of the NFkB pathway that can be used therapeutically to block survival pathways while simultaneously allowing for agents such as TNF or chemotherapeutics to activate apoptotic pathways. The use of such combination therapy has the potential to allow proliferative control of established tumors. Because of the widespread nature of the NFkB survival pathway, such NFkB inhibitors would be expected to be useful in a wide variety of proliferative diseases and mammary cancer is no exception. Recent studies have revealed that mammary tumor cells utilize NFkB in an anti-apoptotic mechanism and display increased NFkB activity that correlates with estrogen-independence. NFkB function is normally controlled by IkB, which holds NFkB in the cytoplasmic. Signals which activate NFkB lead to phosphorylation of IkB, which signals it for ubiquitinmediated proteolysis thereby allowing NFkB to enter the nucleus. The importance of IkB in the survival function of NFkB is demonstrated by the fact that overexpression of nonphosphorylatable IkB blocks NFkB function, allowing for apoptosis.
Because of its critical position in the NFB activation pathway, the IkB ubiquitin ligase represents an important therapeutic target. Blocking its activity would be equivalent to overexpression of non-phosphorylatable IkB and would be expected to lead to inhibition of NFkB. In the last progress report, we described our efforts to understand how the IkB protein is regulated in response to its phosphorylation by IkB kinase (IKK). It is now clear from our work and work of others that phosphorylation of IkB by IKK allows it to interact with a ubiquitin ligase, SCF ß " TRCP (Winston et al., 1999; Maniatis, 1999) . Ubiquitination of IkB by the SCF ß " TRCP leads to the destruction of IkB by the proteasome. SCF complexes function as E3 ubiquitin ligases and are composed of Skp1, the Ring-H2 finger protein Rbx1, the CuM protein, and an F-box protein, in this case ß-TRCP. This complex recognizes IkB in a phosphorylation-dependent manner and catalyzes IkB ubiquitination in vitro, in conjunction with an E2 ubiquitin conjugating enzyme and an E1 activating enzyme. Analysis of the role of ß-TRCP in the destruction of IkB was a major goal of Aim 1. In the past year, we have explored the biochemistry of the interaction of ß-TRCP with IkB using physical and mutagenenic approaches. As described below, this has revealed a consensus sequence recognized by ß-TRCP, which is found in additional targets of IkB, including ß-catenin. In addition, we have identified residues on the surface of ß-TRCP required for recognition of substrates. These studies were major goals of Aim 2.
Body
Identification of a consensus substrate recognition motif for ß-TRCP.
As a first step towards understanding how ß-TRCP interacts with IkB and ß-catenin destruction motifs, we wanted to search for sequences that are able to bind to ß-TRCP. One approach to this problem, which we proposed, is the use of peptide libraries containing a large number of diverse sequences. Sequence analysis of peptides that bind to a particular protein provides a consensus sequence for binding which can then be followed up with more detailed experiments, depending upon the degeneracy observed. Together with Dr. Songyang who developed the peptide library approach, we performed an analysis of ß-TRCP. Because large amounts of immobilized protein is required for this technique, we had to develop a system for expressing large quantities of functional ß-TRCP. Preliminary experiments indicated that expression of ß-TRCP in bacteria was sub-optimal and the protein that could be expressed as incapable of binding to IkB (data not shown). Therefore, we developed an insect cell expression system wherein we co-express untagged ß-TRCP with GSTSkp1. Complexes are then purified using GSH-sepharose. Using this approach we were able to generate sufficient amounts of essentially homogeneous GST-Skp1/ß-TRCP complexes for binding studies.
Because we already knew that ß-TRCP interacts with phospho-serine containing destruction motifs, we used a peptide library containing two fixed phosphoserine residues with the first phosphoserine preceded by a aspartate. Peptide library was incubated with immobilized GST-Skp1/ß-TRCP and the beads washed extensively. Peptide was eluted by treating the complex with acid (pH2) and released peptides subjected to Edman degradation to determine the collection of peptide sequences. The data are shown in Fig. 1 (appendix) . The consensus was 0-
(where $ = a hydrophobic amino acid). Some aspects of this consensus conform to the sequences of IkB and ß-catenin while other aspects do not. For example selection of Y and F residues in the last two positions was not expected, based on the IkB sequence. This suggest that it might be possible to generate a specific inhibitor of ß-TRCP. Several other libraries were tried, including single phosphoserine libraries but these did not bind, suggesting that two phospho-serines are required for binding.
Identification of residues involved in recognition of IkB and ß-catenin by ß-TRCP.
As a second step towards identifying small molecules that interact with ß-TRCP and block association with IkB and ß-catenin, we sought to identify residues in ß-TRCP that are required for this association. ß-TRCP is a member of the WD40 repeat family of proteins and contains 7 WD40 repeats. Proteins containing 7 WD40 repeats, such as ß-transducin, form a ß-propeller structure in which each WD40 repeat forms a blade of the 7-blade propeller. We hypothesized that basic residues (lysine and arginine) located on the surface of ß-TRCP might function in the recognition of phosphorylated IkB and ß-catenin destruction motifs. To examine this question, we developed a model of ß-TRCP based on the known structure of ß-transducin. Using this model, we identified lysine and arginine residues that are conserved among ß-TRCP family members but not other family WD40 containing Fbox proteins. Residues were classified as either being on the surface of the face of the propeller that binds a-transducin, the face of the propeller that binds y-transducin, or buried in the central core of the propeller. Residues identified by this exercise are shown in Fig. 2 (appendix) .
Given the likelihood that ligands bind ß-TRCP from the a-face, we made point mutants in all of the conserved basic residues on this surface. These residues in ß-TRCP were changed to alanine by site-directed mutagenesis and the mutant cDNAs cloned into expression vectors. Proteins were expressed and tested for binding to IkB and ß-catenin destruction motif peptides in either the phosphorylated or unphosphorylated forms. As shown in Figure 3 (appendix), mutations of most of the residue had no effect on the interaction of ß-TRCP with IkB and ß-catenin destruction motifs. However, mutation of two residues -Arg306 and Lys289 -led to dramatic decreases in binding affinity. These two residues are located in the first WD40 repeat, adjacent to the F-box motif. Previous deletion studies have revealed that this WD40 repeat is important for interaction with ß-TRCP targets.
Specificity of ligand binding by WD40 repeat-containing F-box proteins.
As described in the previous progress report, we have cloned a family of mammalian F-box proteins, including WD40 and leucine rich repeat containing proteins. Previously, we had found 5 WD40 repeat containing proteins. In the last year, we have identified 2 additional WD40 repeat containing F-box proteins, Fbw6 and Fbw7. Given this rather large number of F-box proteins, we wondered whether there was a common them to substrate recognition or whether different F-box proteins used different structural elements to interact with targets. To date, the only other WD40-containing F-box protein whose substrate has been identified is Fbw7. We recently found that Fbw7 is responsible for ubiquitin-mediated destruction of cyclin E. Like ß-TRCP, Fbw7 interacts with a short phosphorylated destruction motif in cyclin E, LeuLeu-phosphoThr-Pro-Pro. We used a similar strategy as described for ß-TRCP to identify residues involved in binding of cyclin E to Fbw7. This analysis revealed that three arginine residues were important for the cyclin E interaction (Fig. 4, appendix) . Unlike the situation with ß-TRCP, these residues were located in WD40 repeats 3, 4, and 5. Mutation of these residues independently to alanine either abolished or greatly reduced the interaction of Fbw7 with cyclin E. These data suggest that different WD40 repeat elements confer substrate specificity upon different F-box proteins. This work is currently being written for publication.
WD40 elements alone are insufficient for destruction motif recognition.
Given the results with ß-TRCP and IkB/ß-catenin destruction motifs, we were interested in determining whether isolated WD40 elements could interact with phosphopeptides. We generated ß-TRCP proteins that were truncated after each WD40 repeat and tested these for binding to IkB destruction motifs. Only the full length protein containing all 7 WD40 repeats was capable of binding (data not shown). It is likely that this reflects the absence of structural stability of the WD40 ß-propeller structure when one or more repeats are missing.
Discussion
Activation of NFkB involves an extensive signal transduction pathway that culminates in the destruction of the NFkB inhibitor IkB. We have demonstrated that IkB is ubiquitinated by an SCF ß " TRCP ubiquitin ligase complex. In principle, molecules that block IkB destruction could act as pro-apoptotic agents. F-box proteins such as ß-TRCP function by binding to destruction sequences, and in IkB, the destruction motif is created upon phosphorylation at Ser32 and Ser34. The sequences we have identified by peptide library analysis (Fig. 1) correspond to the sequence of IkB. These sequences also occur in ß-catenin and both biochemical and genetic evidence indicate a role for ß-TRCP in interacting with b-catenin or armadillo in flies (Jiang and Struhl, 1998) . ß-catenin is a component of the Wingless/Wnt signaling pathway and functions with Tcf/Lef transcription factors to regulate patterning and other developmental decisions. Recent work in Xenopus has revealed that expression a ß-TRCP protein lacking the F-box leads to accumulation of ß-catenin and ectopic activation of the Wnt pathway (Marikawa and Elinson, 1998) . This, together with our data linking ß-TRCP to direct recognition of the phosphorylated ß-catenin destruction motif strongly implicates SCFß~T as the ß-catenin ubiquitin ligase. Further studies are required to determine whether any of the many proteins containing the DSG<|)XS motif are also substrates for SCFß-TRCP . Our results also indicate that different F-box proteins employ distinct WD40 repeats to recognize substrates. ß-TRCP employs WD40 repeat number 1 primarily while Fbw7 employs WD40 repeats 3-5. This indicates that agents that interact with distinct structural components of WD40 repeat proteins may display specificity towards individual family members. The crystal structures of F-box proteins associated with their targets will help clarify how destruction motifs are recognized and will facilitate the identification of agents that can block interactions with destruction motifs. 
Conclusion
Aim 2 of this research project seeks to understand how ß-TRCP interacts with IkB, with the hope of exploiting this interaction to block NFkB activation. In principle, small molecules that block the association of IkB with ß -TRCP could block the anti-apoptotic activities of NFkB by maintaining it in the inactive form bound to IkB. One potential limitation of this approach is that ß-TRCP also functions in the ubiquitination of ß-catenin. In the coming year, we plan to further our understanding of the interaction of b-TRCP with other targets and to examine whether blockage of ß-TRCP activity will be proapoptotic. . Analysis of the ß-TRCP homolog Fbw7 and its motifs involved in interaction with cyclin E. A model of Fbw7 was generated and conserved arginine and lysine residues not present in ß-TRCP found (red). These residues were mutated to alanine and in vitro translation products used for binding to GST-cyclin E/Cdk2. The R417 and R457 mutants displayed no detectable binding while the R495 mutant displayed reduced binding.
